Despite challenges such as high attrition rates and adverse events, the trial highlights the value of established therapies ...

This multiyear follow-up of more than 3300 patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) who ...

Panelists express their gratitude for the informative discussion and share their final thoughts on the evolving landscape of ...

On Friday, President-elect Donald Trump announced his nominations to lead the CDC, for FDA Commissioner, and for Surgeon ...

The US has not gotten a grade above a C+ since 2013, as the preterm birth rate has gone up almost a whole percentage point in ...

In the US, liraglutide, semaglutide, and tirzepatide are currently under investigation for their ability to stimulate weight ...

With approval, acoramaidis (Attruby; BridgeBio Pharma) becomes the first agent with a label specifying near-complete ...

The increase in the global burden of interstitial lung disease (ILD) and pulmonary sarcoidosis had the greatest impact on ...

For over 20 years, the Movember Foundation has used its mustache-growing campaign to raise awareness and funds for men's ...

Native Hawaiian and non-Hispanic Black individuals had the highest burden of mortality among patients with early-onset ...

A claims-based study revealed high adherence to phosphorodiamidate morpholino oligomer (PMO) treatments for Duchenne muscular dystrophy (DMD), but highlights limitations in interpreting real-world ...

Patients experienced similar safety and efficacy if they received first-line or later-line treatment for unresectable ...